AVEO Oncology has appointed Matthew Dallas as CFO (chief financial officer) effective from June 1, 2017. Mr. Dallas will be responsible for the Company’s financial strategy and management. He also serve team which governs corporate strategy of the company. He will succeed Keith Ehrlich, whose retirement from the Company was previously announced.
Mr. Dallas has 20 years of financial management experience, including 18 years in the life sciences industry. Most recently, he served as Chief Financial Officer and Treasurer of CoLucid Pharmaceuticals. Prior to CoLucid, Mr. Dallas served as VP of Finance and Treasurer at AVEO from 2011 to 2015. He previously worked at Genzyme Corporation, NEN Life Sciences, and Kimberly-Clark Corporation where he held various positions of increasing responsibility in finance and accounting. Mr. Dallas holds a B.S. in Finance from the University of Tennessee, Knoxville.
AVEVO president and CEO, Michael Bailey said that it is a pleasure to welcome Matt back to the AVEO team, following a successful tenure as chief financial officer at CoLucid. He look forward to Matt’s insights and expertise as AVEO advances their plans for tivozanib and the other programs in their pipeline. He would also like to thank Keith for his contributions and service to the Company, and for supporting Matt through this initial transition period.